Open comment allows for key stakeholders to critically review and identify any errors or gaps in a draft measure prior to its finalization and implementation. It allows for greater transparency in the ASCO measure development process and complies with best practices for measure development. In addition, open comment enables ASCO to engage interested stakeholders (especially patients/patient advocacy groups), provide a higher-quality product to the membership, and facilitate implementation and dissemination efforts.

ASCO measures will be available for open comment for a two- to three-week period. Prospective reviewers must contact ASCO to request to review the draft measure and will be required to sign a non-disclosure and confidentiality agreement before receiving the draft measure. Reviewers must identify themselves by name and affiliation; anonymous comments will not be accepted. Measures staff will review and summarize comments and bring relevant comments to the measure panel chairs, and to the entire technical expert panel if necessary. Any changes made from the open comment process will be reviewed by the entire panel prior to Measures Steering Group approval. Comments are advisory only and ASCO is not bound to make any changes based on feedback from open comment. ASCO will not respond to reviewers or post any responses to comments.

Available for Open Comment

There are currently no measures available for public comment. Please check back in the coming weeks to provide feedback on ASCO measures.

Open comment allows for key stakeholders to critically review and identify any errors or gaps in a draft measure prior to its finalization. It allows for greater transparency in the ASCO measure development process. In addition, open comment enables ASCO to engage interested stakeholders (especially patients/patient advocacy groups), provide a higher-quality product to the membership, and facilitate implementation and dissemination efforts.

To comment on the measure(s), we ask interested reviewers to complete a confidentiality agreement prior to commenting on the measure(s).  Please email measurement@asco.org to receive the confidentiality agreement and access to the survey containing the draft measure narratives.

Measures staff will review and summarize comments and bring relevant comments to the TEP chairs, and to the entire panel if necessary. Any changes made from the open comment process will be reviewed by the entire panel prior to MSG approval. Comments are advisory only and ASCO is not bound to make any changes based on feedback from open comment. ASCO will not respond to reviewers or post any responses to comments.

Measures in Development

Listed below are the current de novo measures and measures under maintenance. Concepts prioritized for development by the Measures Steering Group are listed by disease site. To submit a concept for consideration, visit the Measure Intake Form. To learn more about the ASCO Measure development process, access the Measures Methodology.

Gynecologic Cancer

  • Germline Testing in Ovarian Cancer
  • Radical Hysterectomy Surgical Approach in Cervical Cancer

Gastrointestinal Cancer

  • BRAF testing for metastatic Colorectal Cancer

Cross-cutting Immuno-Oncology

  • Gene expression testing (e.g. MSI/MMR, programmed death-ligand 1 (PD-L1)) to inform the use of immune checkpoint inhibitors for a variety of unresectable, metastatic solid tumors.